Treatment with 2 μM of the δ-tocotrienol oxazine derivative, compound 44, alone had little or no effect on +SA mammary tumor cell VEGF synthesis as compared to the vehicle-treated control group (Figure 7). Here, VEGFA is linked to breast cancer.